Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL R SAPER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine

NPI
1891888095
CMS profile
358295
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$34.38

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $34.38 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $34.38 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL R SAPER

NPI 1891888095 · CMS profile ID 358295

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1891888095?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $34.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $34.3811/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145965516 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $867.79 4
PY2024 $34.38 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,643.58 208
PY2024 Principal investigator $778,871.45 258
PY2023 Recipient $188,670.14 42
PY2023 Principal investigator $817,852.03 284
PY2022 Recipient $694.00 1
PY2022 Principal investigator $856,999.67 290
PY2021 Principal investigator $1,105,932.40 208
PY2020 Principal investigator $729,753.82 96
PY2019 Recipient $20,043.40 4
PY2019 Principal investigator $688,115.98 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

208 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202534509
Principal investigator 1 ABBVIE INC. $398.76 12/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202534511
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534715
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202534717
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202534719
Principal investigator 1 PFIZER INC. $2,835.00 12/31/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702352
Principal investigator 1 PFIZER INC. $2,835.00 12/31/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702706
Principal investigator 1 PFIZER INC. $2,835.00 12/31/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702962
Principal investigator 1 PFIZER INC. $11,519.60 12/31/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228744966
Principal investigator 1 PFIZER INC. $9,219.00 12/27/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228746906
Principal investigator 1 PFIZER INC. $1,250.00 12/24/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228726680
Principal investigator 1 PFIZER INC. $6,510.00 12/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228745454
Principal investigator 1 ABBVIE INC. $1,400.25 12/18/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202531186
Principal investigator 1 ABBVIE INC. $6,000.00 12/18/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202531188
Principal investigator 1 PFIZER INC. $3,194.30 12/17/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228720431
Principal investigator 1 PFIZER INC. $21.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702350
Principal investigator 1 PFIZER INC. $141.75 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702354
Principal investigator 1 PFIZER INC. $151.20 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702404
Principal investigator 1 PFIZER INC. $73.15 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702406
Principal investigator 1 PFIZER INC. $108.15 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702450
Principal investigator 1 PFIZER INC. $141.75 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702452
Principal investigator 1 PFIZER INC. $93.45 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702454
Principal investigator 1 PFIZER INC. $77.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702506
Principal investigator 1 PFIZER INC. $93.45 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702508
Principal investigator 1 PFIZER INC. $21.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702510
Principal investigator 1 PFIZER INC. $53.55 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702560
Principal investigator 1 PFIZER INC. $79.10 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702562
Principal investigator 1 PFIZER INC. $99.05 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702564
Principal investigator 1 PFIZER INC. $90.65 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702648
Principal investigator 1 PFIZER INC. $105.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702708
Principal investigator 1 PFIZER INC. $63.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702710
Principal investigator 1 PFIZER INC. $95.55 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702742
Principal investigator 1 PFIZER INC. $105.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702744
Principal investigator 1 PFIZER INC. $14.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702790
Principal investigator 1 PFIZER INC. $99.05 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702792
Principal investigator 1 PFIZER INC. $77.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702794
Principal investigator 1 PFIZER INC. $73.15 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702844
Principal investigator 1 PFIZER INC. $14.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702846
Principal investigator 1 PFIZER INC. $98.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702848
Principal investigator 1 PFIZER INC. $70.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702860
Principal investigator 1 PFIZER INC. $108.15 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702900
Principal investigator 1 PFIZER INC. $53.55 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702902
Principal investigator 1 PFIZER INC. $98.70 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702904
Principal investigator 1 PFIZER INC. $88.90 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702932
Principal investigator 1 PFIZER INC. $79.10 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702934
Principal investigator 1 PFIZER INC. $179.20 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702964
Principal investigator 1 PFIZER INC. $90.65 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702966
Principal investigator 1 PFIZER INC. $88.90 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703014
Principal investigator 1 PFIZER INC. $90.65 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703016
Principal investigator 1 PFIZER INC. $151.20 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703018
Principal investigator 1 PFIZER INC. $63.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703062
Principal investigator 1 PFIZER INC. $70.00 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703064
Principal investigator 1 PFIZER INC. $179.20 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703112
Principal investigator 1 PFIZER INC. $95.55 12/06/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703114
Principal investigator 1 ABBVIE INC. $12,278.25 12/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527402
Principal investigator 1 PFIZER INC. $12,986.40 11/26/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228724582
Principal investigator 1 PFIZER INC. $9,693.77 11/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728335
Principal investigator 1 PFIZER INC. $1,310.72 11/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729201
Principal investigator 1 PFIZER INC. $261.90 11/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047778
Principal investigator 1 ABBVIE INC. $164.03 11/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202523257
Principal investigator 1 ABBVIE INC. $2,708.44 11/05/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202521815
Principal investigator 1 ABBVIE INC. $415.80 11/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520327
Principal investigator 1 ABBVIE INC. $2,100.00 11/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520329
Principal investigator 1 ABBVIE INC. $4,294.00 11/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520381
Principal investigator 1 PFIZER INC. $7,385.00 11/04/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228729069
Principal investigator 1 PFIZER INC. $7,145.60 11/04/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228737721
Principal investigator 1 ABBVIE INC. $1,959.00 10/30/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202519729
Principal investigator 1 PFIZER INC. $887.49 10/30/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228737655
Principal investigator 1 PFIZER INC. $1,500.00 10/23/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702402
Principal investigator 1 PFIZER INC. $2,500.00 10/23/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702646
Principal investigator 1 PFIZER INC. $4,000.00 10/23/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702740
Principal investigator 1 PFIZER INC. $1,000.00 10/23/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702930
Principal investigator 1 PFIZER INC. $2,000.00 10/23/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228703060
Principal investigator 1 PFIZER INC. $2,461.80 10/21/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228755153
Principal investigator 1 PFIZER INC. $1,310.72 10/17/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228733671
Principal investigator 1 PFIZER INC. $2,250.00 10/14/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228737089
Principal investigator 1 ABBVIE INC. $1,656.25 10/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514503
Principal investigator 1 ABBVIE INC. $4,833.00 10/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514505
Principal investigator 1 PFIZER INC. $2,300.00 10/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228733679
Principal investigator 1 PFIZER INC. $17,978.71 10/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228739238
Principal investigator 1 PFIZER INC. $9,204.32 10/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228739246
Principal investigator 1 PFIZER INC. $8,282.40 10/08/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228741460
Principal investigator 1 PFIZER INC. $1,774.98 09/25/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743623
Principal investigator 1 PFIZER INC. $8,510.60 09/24/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228759379
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,154.25 09/23/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047776
Principal investigator 1 ABBVIE INC. $9,328.50 09/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509614
Principal investigator 1 PFIZER INC. $3,080.00 09/03/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228724052
Principal investigator 1 PFIZER INC. $15,147.02 09/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743207
Principal investigator 1 PFIZER INC. $410.40 09/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743510
Principal investigator 1 PFIZER INC. $6,041.00 09/03/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228749301
Principal investigator 1 PFIZER INC. $1,360.50 08/29/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228787038
Principal investigator 1 PFIZER INC. $5,643.00 08/27/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228752333
Principal investigator 1 PFIZER INC. $6,728.40 08/22/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228786442
Principal investigator 1 ABBVIE INC. $405.00 08/14/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202504889
Principal investigator 1 ABBVIE INC. $40.50 08/14/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202504891
Principal investigator 1 ABBVIE INC. $13,500.00 08/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202503373
Principal investigator 1 ABBVIE INC. $8,734.50 08/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503375
Principal investigator 1 ABBVIE INC. $1,331.00 08/05/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202502042
Principal investigator 1 PFIZER INC. $11,541.60 08/02/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228768187
Principal investigator 1 H. Lundbeck A S $950.39 08/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251773112
Principal investigator 1 H. Lundbeck A S $615.16 08/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251773117
Principal investigator 1 H. Lundbeck A S $1,500.00 08/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251773177
Principal investigator 1 H. Lundbeck A S $5,000.00 08/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251773181
Principal investigator 1 H. Lundbeck A S $500.00 08/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) No dispute reported 06/30/2026 1251773185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $477.90 07/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047772
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 07/31/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047774
Principal investigator 1 ABBVIE INC. $121.50 07/30/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202500444
Principal investigator 1 PFIZER INC. $8,270.87 07/29/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228766555
Principal investigator 1 H. Lundbeck A S $1,370.26 07/16/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251772340
Principal investigator 1 H. Lundbeck A S $1,500.00 07/16/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251772351
Principal investigator 1 H. Lundbeck A S $5,000.00 07/16/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) No dispute reported 06/30/2026 1251772356
Principal investigator 1 PFIZER INC. $8,911.00 07/11/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228763005
Principal investigator 1 ABBVIE INC. $2,293.93 07/10/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497774
Principal investigator 1 ABBVIE INC. $81.00 07/10/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202497786
Principal investigator 1 ABBVIE INC. $1,500.00 07/10/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202497788
Principal investigator 1 ABBVIE INC. $1,249.75 07/09/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497570
Principal investigator 1 ABBVIE INC. $328.20 07/08/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202497040
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.00 07/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047768
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $143.10 07/04/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047770
Principal investigator 1 ABBVIE INC. $6,952.00 07/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202494073
Principal investigator 1 ABBVIE INC. $9,105.75 07/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494179
Principal investigator 1 PFIZER INC. $9,871.40 06/26/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228790523
Principal investigator 1 H. Lundbeck A S $2,500.00 06/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771438
Principal investigator 1 H. Lundbeck A S $1,000.00 06/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771441
Principal investigator 1 H. Lundbeck A S $1,500.00 06/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771445
Principal investigator 1 H. Lundbeck A S $8,000.00 06/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771449
Principal investigator 1 H. Lundbeck A S $5,000.00 06/20/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771453
Principal investigator 1 PFIZER INC. $1,112.90 06/19/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228723678
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 06/19/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047734
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 06/19/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047736
Principal investigator 1 PFIZER INC. $2,500.00 06/17/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702784
Principal investigator 1 PFIZER INC. $2,000.00 06/17/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702838
Principal investigator 1 PFIZER INC. $1,000.00 06/17/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702958
Principal investigator 1 PFIZER INC. $49.00 06/17/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228710996
Principal investigator 1 H. Lundbeck A S $70.00 06/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251771126
Principal investigator 1 PFIZER INC. $2,236.68 06/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775161
Principal investigator 1 ABBVIE INC. $622.65 06/11/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202490849
Principal investigator 1 PFIZER INC. $11,000.00 06/07/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228793294
Principal investigator 1 PFIZER INC. $500.00 06/05/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774756
Principal investigator 1 ABBVIE INC. $1,984.00 06/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202487851
Principal investigator 1 ABBVIE INC. $17,354.25 06/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487853
Principal investigator 1 PFIZER INC. $8,990.20 05/30/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228765587
Principal investigator 1 PFIZER INC. $1,500.00 05/28/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228762378
Principal investigator 1 PFIZER INC. $500.00 05/22/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228762718
Principal investigator 1 ABBVIE INC. $6,338.25 05/07/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483715
Principal investigator 1 ABBVIE INC. $3,290.00 05/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202482039
Principal investigator 1 ABBVIE INC. $43.20 05/01/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202480821
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,172.85 04/28/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047732
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,840.15 04/28/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047766
Principal investigator 1 PFIZER INC. $7,609.20 04/24/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION No dispute reported 06/30/2026 1228777079
Principal investigator 1 PFIZER INC. $9,464.24 04/24/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777223
Principal investigator 1 PFIZER INC. $6,791.40 04/24/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228797179
Principal investigator 1 PFIZER INC. $500.00 04/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702894
Principal investigator 1 PFIZER INC. $500.00 04/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702898
Principal investigator 1 PFIZER INC. $1,197.00 04/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702924
Principal investigator 1 PFIZER INC. $250.00 04/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702928
Principal investigator 1 PFIZER INC. $500.00 04/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228710934
Principal investigator 1 PFIZER INC. $5,566.40 04/05/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228781243
Principal investigator 1 ABBVIE INC. $10,611.00 04/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202472433
Principal investigator 1 ABBVIE INC. $4,196.00 04/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202472436
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,488.40 03/25/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047764
Principal investigator 1 PFIZER INC. $1,017.45 03/20/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702736
Principal investigator 1 PFIZER INC. $2,008.30 03/20/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702842
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $40.50 03/14/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047762
Principal investigator 1 ABBVIE INC. $249.75 03/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202463221
Principal investigator 1 ABBVIE INC. $1,129.50 03/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202463256
Principal investigator 1 ABBVIE INC. $1,350.00 03/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202463275
Principal investigator 1 PFIZER INC. $958.03 03/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228720335
Principal investigator 1 ABBVIE INC. $12,048.75 03/07/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460031
Principal investigator 1 ABBVIE INC. $8,248.00 03/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202457195
Principal investigator 1 H. Lundbeck A S $1,500.00 02/19/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251767516
Principal investigator 1 H. Lundbeck A S $1,000.00 02/19/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251767520
Principal investigator 1 PFIZER INC. $1,197.00 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702644
Principal investigator 1 PFIZER INC. $1,389.85 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702734
Principal investigator 1 PFIZER INC. $49.00 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702738
Principal investigator 1 PFIZER INC. $49.00 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702926
Principal investigator 1 PFIZER INC. $250.00 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702956
Principal investigator 1 PFIZER INC. $1,875.30 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228710936
Principal investigator 1 PFIZER INC. $2,008.30 02/19/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228710938
Principal investigator 1 PFIZER INC. $11,000.00 02/14/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228757815
Principal investigator 1 ABBVIE INC. $705.00 02/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202451018
Principal investigator 1 ABBVIE INC. $3,675.00 02/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202451231
Principal investigator 1 PFIZER INC. $1,000.00 02/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228766025
Principal investigator 1 ABBVIE INC. $13,263.75 02/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447164
Principal investigator 1 PFIZER INC. $1,000.00 02/06/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768134
Principal investigator 1 ABBVIE INC. $2,612.00 02/05/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202444159
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,510.30 01/30/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047912
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.80 01/21/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047760
Principal investigator 1 PFIZER INC. $500.00 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702786
Principal investigator 1 PFIZER INC. $1,881.95 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228702788
Principal investigator 1 PFIZER INC. $49.00 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702840
Principal investigator 1 PFIZER INC. $399.00 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702896
Principal investigator 1 PFIZER INC. $49.00 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702960
Principal investigator 1 PFIZER INC. $250.00 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228703110
Principal investigator 1 PFIZER INC. $1,689.10 01/18/2025 Non-covered Recipient Entity
Michigan Headache and Neurological Institute
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228710994
Principal investigator 1 PFIZER INC. $2,498.31 01/16/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765862
Principal investigator 1 PFIZER INC. $1,310.72 01/16/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767458
Principal investigator 1 ABBVIE INC. $5,000.00 01/14/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202438257
Principal investigator 1 ABBVIE INC. $5,000.00 01/13/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202438093
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,776.50 01/07/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age No dispute reported 06/30/2026 1244047758
Principal investigator 1 H. Lundbeck A S $500.00 01/03/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE
A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) No dispute reported 06/30/2026 1251766133
Principal investigator 1 ABBVIE INC. $663.19 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202433729
Principal investigator 1 ABBVIE INC. $1,500.00 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202433794
Principal investigator 1 ABBVIE INC. $4,818.00 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202433797
Principal investigator 1 ABBVIE INC. $2,100.00 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEADACHE AND
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202433801
Principal investigator 1 Amgen Inc. $31,508.58 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246644661
Principal investigator 1 Amgen Inc. $126,317.16 01/02/2025 Non-covered Recipient Entity
MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246644663